There is one clinical trial.
The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in
reducing the rate of hospitalization or death in non-hospitalized participants with early
stage coronavirus disease 2019 (COVID-19) and to evaluate the safety of RDV administered in
an outpatient setting.
Primary Outcomes
Measure: Composite Endpoint Measuring Proportion of Participants Hospitalized or Death From Any Cause by Day 14. Time: From date of randomization up to Day 14
Measure: Proportion of Participants Experiencing Treatment-Emergent Adverse Events Time: From date of randomization up to 3 days plus 30 days
Secondary Outcomes
Measure: All-cause Mortality at Day 28 Time: Day 28
Measure: Rate of Hospitalization by Day 28 Time: Day 28
Measure: Time-weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load from Baseline to Day 7 Time: Baseline; Day 7
Measure: Time to Resolution of COVID-19-Related Symptoms Time: First Dose Date Up to Day 28